Intensive Care Unit-Acquired Bacteremia in Mechanically Ventilated Patients: Clinical Features and Outcomes

Hsin-Kuo Ko1,2,3, Wen-Kuang Yu1,2, Te-Cheng Lien2, Jia-Horng Wang2, Arthur S. Slutsky3,4, Haibo Zhang3,5, Yu Ru Kou1,6

1 Institute of Physiology, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC, 2 Department of Respiratory Therapy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC, 3 The Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada, 4 Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada, 5 Department of Anesthesia, Department of Physiology, Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada, 6 Institute of Emergency and Critical Care Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC

Abstract

Intensive care unit (ICU)-acquired bacteremia (IAB) is associated with high medical expenditure and mortality. Mechanically ventilated patients represent one third of all patients admitted to ICU, but the clinical features and outcomes in mechanically ventilated patients who develop IAB remain unknown. We conducted a 3-year retrospective observational cohort study, and 1,453 patients who received mechanical ventilation on ICU admission were enrolled. Among patients enrolled, 126 patients who had developed IAB ≥48 hours after ICU admission were identified. The study patients were divided into IAB and no IAB groups, and clinical characteristics of IAB based on specific bacterial species were further analyzed. The multivariate Cox regression analysis showed that ventilator support for chronic obstructive pulmonary disease and congestive heart failure, and patients admitted from nursing home were the independent risk factors for developing IAB. Patients with IAB were significantly associated with longer length of ICU stay, prolonged ventilator use, lower rate of successful weaning, and higher rate of ventilator dependence and ICU mortality as compared to those without IAB. IAB was the independent risk factor for ICU mortality (HR, 1.510, 95% CI 1.054–1.123; p = 0.010). The clinical characteristics of IAB related to specific bacterial species included IAB due to Pseudomonas aeruginosa being likely polymicrobial, lung source and prior antibiotic use; Escherichia coli developing earlier and from urinary tract source; methicillin-resistant Staphylococcus aureus related to central venous catheter and multiple sets of positive hemoculture; and Elizabethkingia meningoseptica significantly associated with delayed/inappropriate antibiotic treatment. In summary, IAB was significantly associated with poor patient outcomes in mechanically ventilated ICU patients. The clinical features related to IAB and clinical characteristics of IAB based on specific bacterial species identified in our study may be utilized to refine the management of IAB.

Introduction

Nosocomial infection is one of the leading causes of death and is associated with high medical expenditure [1–5]. Among nosocomial infections in the ICU, it has been reported that ICU-acquired bacteremia (IAB) contributes to an approximately 33% mortality rate [5–6]. Notably, critically ill patients undergoing mechanical ventilation (MV) represent one third of all patients admitted to ICU [9], but the clinical features and outcomes in mechanically ventilated patients who develop IAB have not yet been investigated. Furthermore, the influence of IAB on ventilator outcomes including successful weaning of ventilator, ventilator days and ventilator dependence remains unknown.

A major challenge at bedside is that intensivists may not have sufficient information to identify ICU patients at the risk of developing IAB and to distinguish the definite bacterial species prior to prescription of appropriate antibiotics. Although some studies report the predisposing factors for developing IAB [6,10], it is uncertain whether the information originated from critically ill patients with and without MV can be applicable to mechanically ventilated patients and to refine the management of IAB. A number of studies also investigate nosocomial bacteremia in critically ill patients and focus on specific bacterial species [11–15]. These studies report clinical features related to one of several specific bacterial species and offer the information for intensivists to refine the management of IAB. However, the lack of comparative analysis among several bacterial species still leads to a difficulty for intensivists in differentiating the types of pathogens prior to prescription of appropriate antibiotics. The clinical characteristics of IAB related to specific bacterial species is critical for the management of IAB and may help improve the quality of care for ICU patients.

The aims of the study were two-fold: 1) To describe the clinical features of IAB in mechanically ventilated ICU patients, and to define the influence of IAB on patient outcomes; and 2) To identify the risk factors for developing IAB and to describe the
clinical characteristics of IAB based on bacterial species. The results of our study might be utilized by intensivists to identify mechanically ventilated ICU patients who are at the risk of IAB and to refine the management of IAB based on clinical characteristics of specific bacterial species.

Materials and Methods

Ethics statement
We consulted with the institutional review board (IRB) of Taipei Veterans General Hospital, and informed consent was waived under the approval of our IRB according to the institutional guideline for a retrospective observational study. The study was registered at the IRB of Taipei Veterans General Hospital (IRB 97-08-24A), and the date of approval was September 4, 2008.

Design, setting and patients
The retrospective observational cohort study was designed in January 2008 and was conducted in a 35-bed adult respiratory ICU in Taipei Veterans General Hospital, a tertiary teaching hospital in northern Taiwan. Patients were admitted from home, nursing home, local hospital, ordinary ward and other ICU for intensive critical care and/or the discontinuation of mechanical ventilator. All records of consecutive patients admitted to the ICU between July 1, 2006 and June 30, 2009 were retrospectively reviewed. Patients who received mechanical ventilation on ICU admission were enrolled and patients were excluded from the study if they received only noninvasive positive pressure ventilation or oxygen therapy on ICU admission, 2) received invasive mechanical ventilation for less than 72 h after ICU admission, 3) bacteremia had developed within 48 h of ICU admission, or if 4) fungus infection was identified in blood culture.

Measurements
The patient database collection included age, gender, comorbidities, APACHE II score [16], reasons for mechanical ventilation, sources of patients, ICU days, ventilator days, ICU mortality, and ICU discharge deposition. Blood culture and culture from the tip of the central venous or arterial catheter with at least 10^3 colony-forming units and in blood culture. Antibiotic therapy was defined as the same microorganism discovered in the tip of the central venous or arterial catheter with at least 10^3 colony-forming units and in blood culture. Antibiotic therapy was defined as appropriateness if antibiotic was active in vitro against the causative microorganisms based on the result of antimicrobial susceptibility test and when the route of administration and dosage conformed to current medical standards. An inappropriate antibiotic therapy was termed otherwise.

Statistical analysis
SPSS software (version 15.0; SPSS Inc., Chicago, IL) was used for all analyses. Continuous variables were compared using the Student t-test for normally distributed variables and the Mann–Whitney U test and the Kruskal-Wallis test for non-normally distributed variables. Pearson’s chi-square or Fisher’s exact test was performed to compare categorical variables. A multivariate Cox regression model performed by the method of forward stepwise technique was applied using the variables associated with IAB and ICU mortality as a univariate analysis. All continuous data were presented as means ± standard deviations or medians with interquartile range. A p value <0.05 was considered statistically significant, and all p values were two-sided.

Results
Baseline characteristics of the study patients
A total of 1,504 patients were admitted to the ICU during the study period. Forty-seven patients were excluded who received noninvasive positive pressure ventilation (n = 20), and who only received oxygen therapy on ICU admission (n = 27). A total of 1,457 patients who received MV on ICU admission were reviewed. Among these patients, 4 patients who developed bacteremia within 48 hours of ICU admission were excluded. Thus 1,453 patients receiving MV on ICU admission were enrolled in the study (Figure 1). The median age and mean APACHE II score on ICU admission of study patients were 80 (76–85) years and 18.8 (±5.4), respectively. Overall ICU mortality was 15.8% (230/1453). Among the study patients, 126 (8.7%),
126/1453) bacteremic patients developed IAB after a median of 16 days (10–28) after ICU admission (Figure 2) and a median of 27 days (13–41) after initiating MV. A total of 134 pathogens associated with the first episode of IAB were depicted in Table 1, which included gram-negative bacteria recovered in 111 episodes (82.8%, 111/134) and gram-positive bacteria recovered in 23 episodes (17.2%, 23/134). A total of 143 episodes of IAB, including 17 subsequent episodes, were identified over the study period, representing a cumulative incidence of 4.2 episodes per 1,000 ICU days. Polymicrobial bacteremia was observed in 8 patients (6.3%, 8/126). Primary bacteremia was observed in 41 bacteremic patients (32.5%, 41/126). In 126 patients with IAB, 85 patients developed secondary bacteremia, and the sources of IAB were identified as lungs (61.2%, 52/85), central venous catheter (21.2%, 18/85), urinary tract (16.4%, 14/85) and pleural cavity (1.1%, 1/85). The empiric antimicrobial therapy was appropriate for 69 patients with IAB (54.8%, 69/126).

Figure 1. Flowchart of the study protocol. IAB, intensive care unit-acquired bacteremia.

doi:10.1371/journal.pone.0083298.g001

Figure 2. The mode of IAB development based on the numbers of IAB patients and the day of IAB identification after ICU admission.
doi:10.1371/journal.pone.0083298.g002
The risk factors for developing IAB

Clinical features of the study patients with and without IAB were presented in Table 2. Mechanically ventilated ICU patients who developed IAB were older age (p = 0.038), had higher APACHE II score on ICU admission (p = 0.013), and location prior to ICU admission was mostly nursing homes (p = 0.015) rather than home (p = 0.020), and were significantly associated with the causes of respiratory failure due to chronic obstructive pulmonary disease (COPD) (p = 0.018) and congestive heart failure (CHF) (p < 0.001) as compared to those patients without IAB. In the multivariate Cox regression analysis of the potential risk factors for the development of IAB, ventilator support due to COPD (HR 2.057, 95% CI 1.342–3.154; p = 0.001) and CHF (HR 2.028, 95% CI 1.351–3.039; p = 0.001), and patients admitted form nursing home (HR 3.584, 95% CI 1.121–11.494; p = 0.031) remained as the independent risk factors (Table 3).

IAB and patient outcomes

The mechanically ventilated ICU patients who developed IAB were significantly associated with longer length of ICU stay (44.8±26.3 vs. 21.3±17.8 days, p < 0.001), prolonged ventilator days (55.5±44.8 vs. 31.2±25.5 days, p < 0.001), lower rate of successful weaning (37.3 vs. 79.8%, p < 0.001), higher rate of being transferred to respiratory ward due to ventilator dependence (7.1 vs. 1.9%, p = 0.032), and higher ICU mortality rate (46.4 vs. 12.7%, p < 0.001) as compared to those patients without IAB (Table 2; Figures 3A-E). The mean values of increase in APACHE II score from ICU admission to IAB development in IAB patients with APACHE II ≥ 25, 15–24 and < 15 were 1.5, 6.5 and 10.5, respectively. Moreover, IAB significantly contributed to the higher rate of ICU mortality across a wide range of APACHE II score (Figure 3F). The results of multivariate Cox regression analysis showed that APACHE II on ICU admission and IAB were the independent risk factors for ICU mortality (HR 1.056, 95% CI 1.028–1.084; p < 0.001 and HR 1.510, 95% CI 1.054–1.123; p = 0.010, respectively) (Table 4).

Baseline characteristics of the IAB patients based on specific bacterial species

The baseline characteristics of IAB based on the most common pathogens are shown in Table 3. IAB due to Klebsiella pneumoniae and Pseudomonas aeruginosa mostly originated from the lungs (p = 0.031 and p < 0.001, respectively). IAB due to Escherichia coli frequently originated from the urinary tract (p = 0.020) and methicillin-resistant Staphylococcus aureus (MRSA) was significantly related to the infection source of CVC (p = 0.002). IAB due to Elizabethkingia meningoseptica was mostly classified as primary bacteremia (p = 0.002). The patients with IAB due to P. aeruginosa were more likely polymicrobial (p = 0.019) and were significantly associated with prior antibiotic use (p = 0.008) as compared to patients with IAB due to non-P. aeruginosa. Patients with IAB due to E. meningoseptica and MRSA significantly showed multiple sets of positive blood culture compared to those with IAB due to non-E. meningoseptica and non-MRSA (p = 0.001 and p = 0.048 respectively). IAB due to E. coli significantly occurred earlier than IAB due to non-E. coli (p = 0.012).

Clinical characteristics at the onset of IAB based on specific bacterial species

Clinical characteristics at the onset of IAB and patient outcomes in IAB patients based on the six common pathogens are shown in Table 6. The patients with IAB due to P. aeruginosa had higher serum levels of blood urea nitrogen (BUN) (114.3±63.7 vs. 94.8±50.9 mg/dl, p = 0.030) and greater numbers of organ dysfunction (1.6±1.4 vs. 0.9±1.1, p = 0.040) as compared to those patients with IAB due to non-P. aeruginosa. IAB due to E. meningoseptica was significantly associated with a lower rate of effective empiric antibiotic (16.7 vs. 61.1%, p = 0.001), and the increased time delay until appropriate antibiotics (77.5±33.8 vs. 33.8±37.8 hours, p < 0.001). IAB due to E. meningoseptica was significantly associated with lower serum levels of BUN (60.9±25.6 vs. 92.8±56.5 mg/dl, p = 0.024), lower rate of shock (11.1 vs. 39.3%, p = 0.030) and less need for acute hemodialysis (0 vs. 19.4%, p = 0.041) as compared to IAB due to non-E. meningoseptica. IAB due to Acinetobacter baumanii seemed to have better outcomes, including greater 28-day ventilator-free days (6.7±8.3 vs. 3.6±7.2 days, p = 0.048) and lower rate of ICU mortality (9.1 vs. 51.7%, p = 0.017) as compared to IAB due to non-A. baumanii.

Discussion

Bacteremia is one of the most common nosocomial infections and is harmful to critically ill patients [6,19–21]. In the current study, we found that mechanically ventilated ICU patients with IAB compared to those without IAB had longer length of ICU stay (44.8±26.3 vs. 21.3±17.8 days, p < 0.001), prolonged ventilator days (55.5±44.8 vs. 31.2±25.5 days, p < 0.001), lower rate of successful weaning (37.3 vs. 79.8%, p < 0.001), higher rate of being transferred to respiratory ward due to ventilator dependence (7.1 vs. 1.9%, p = 0.032), and higher ICU mortality rate (46.4 vs. 12.7%, p < 0.001) as compared to those patients without IAB (Table 2; Figures 3A-E). The mean values of increase in APACHE II score from ICU admission to IAB development in IAB patients with APACHE II ≥ 25, 15–24 and < 15 were 1.5, 6.5 and 10.5, respectively. Moreover, IAB significantly contributed to the higher rate of ICU mortality across a wide range of APACHE II score (Figure 3F). The results of multivariate Cox regression analysis showed that APACHE II on ICU admission and IAB were the independent risk factors for ICU mortality (HR 1.056, 95% CI 1.028–1.084; p < 0.001 and HR 1.510, 95% CI 1.054–1.123; p = 0.010, respectively) (Table 4).
## Table 2. Clinical Features and Outcomes in the Study Patients with and without IAB.

|                          | All (n = 1453) | IAB (n = 126) | No IAB (n = 1,327) | p     |
|--------------------------|----------------|---------------|--------------------|-------|
| Age* (y)                 | 80 (76–85)     | 82 (78–85)    | 80 (75–85)         | 0.038 |
| Male/female              | 1104/349       | 98/28         | 1006/321           | 0.664 |
| APACHE II score on ICU admission | 18.8±5.4       | 19.8±5.3      | 18.7±5.4           | 0.013 |
| Location prior to ICU admission |                |               |                    |       |
| Home                     | 662 (45.6)     | 42 (33.3)     | 620 (46.7)         | 0.020 |
| Ordinary ward            | 377 (25.9)     | 39 (31.0)     | 338 (25.5)         | 0.202 |
| Intensive care unit      | 293 (20.2)     | 25 (19.8)     | 268 (20.2)         | 1.000 |
| Local hospital           | 98 (6.7)       | 13 (10.3)     | 85 (6.4)           | 0.096 |
| Nursing home             | 12 (0.8)       | 4 (3.2)       | 8 (0.6)            | 0.015 |
| Causes for ventilator support |                |               |                    |       |
| Pneumonia                | 375 (25.8)     | 30 (23.8)     | 345 (26.0)         | 0.670 |
| COPD                     | 283 (19.5)     | 35 (27.8)     | 248 (18.7)         | 0.018 |
| CHF                      | 209 (14.4)     | 42 (33.3)     | 167 (12.6)         | <0.001|
| Neurological disease     | 87 (6.0)       | 6 (4.8)       | 81 (6.1)           | 0.695 |
| Sepsis and septic shock | 57 (3.9)       | 4 (3.2)       | 53 (4.0)           | 0.813 |
| Bronchial asthma         | 29 (2.0)       | 4 (3.2)       | 25 (1.9)           | 0.309 |
| Acute myocardial infarction and CAD | 28 (1.9) | 0 (0) | 28 (2.1) | 0.165 |
| Pneumothorax             | 10 (0.7)       | 1 (0.8)       | 9 (0.7)            | 0.597 |
| ICU stay (d)             | 23.3±19.8      | 44.8±26.3     | 21.3±17.8          | <0.001|
| Total ventilator day (d) | 33.3±27.0      | 55.5±44.8     | 31.2±25.5          | <0.001|
| Successful weaning       | 1106 (76.1)    | 47 (37.3)     | 1059 (79.8)        | <0.001|
| ICU mortality            | 230 (15.8)     | 61 (48.4)     | 169 (12.7)         | <0.001|
| ICU discharged deposition (n = 1223) | | | | |
| Ordinary ward            | 868 (70.9)     | 48 (73.2)     | 820 (70.8)         | 1.000 |
| Home                     | 140 (11.5)     | 2 (3.6)       | 138 (11.9)         | 0.055 |
| Nursing home             | 83 (6.8)       | 2 (3.6)       | 81 (7.0)           | 0.425 |
| Intensive care unit      | 32 (2.7)       | 1 (1.8)       | 31 (2.7)           | 1.000 |
| Local hospital           | 72 (5.9)       | 7 (10.7)      | 65 (5.6)           | 0.141 |
| Respiratory care ward    | 27 (2.2)       | 5 (7.1)       | 22 (1.9)           | 0.032 |

Data are reported as mean ± S.D. or number (%). * Values are reported as median (interquartile range). APACHE, Acute Physiology and Chronic Health Evaluation; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; IAB, intensive care unit-acquired bacteremia; ICU, intensive care unit.

doi:10.1371/journal.pone.0083298.t002

## Table 3. Univariate and Multivariate Cox Regression Analysis of Potential Risk Factors for the Development of IAB in the Study Patients (n = 1,453).

|                        | Univariate HR (95% CI) | Multivariate HR (95% CI) |
|------------------------|------------------------|--------------------------|
| Age                    | 1.000 (0.985–1.016)    | -                        |
| APACHE II on ICU admission | 1.010 (0.977–1.045)    | -                        |
| Location prior to ICU admission |              |                          |
| Home                  | 0.828 (0.570–1.201)    | -                        |
| Nursing home          | 6.802 (2.481–18.518)** | 3.584 (1.121–11.494)**   |
| Cause for ventilator support |                   |                          |
| COPD                  | 1.557 (1.053–2.304)*   | 2.057 (1.342–3.154)*     |
| CHF                   | 2.369 (1.631–3.436)**  | 2.028 (1.351–3.039)**    |

* p<0.05; ** p<0.001. Multivariate Cox regression performed by the method of forward stepwise technique was applied. APACHE, Acute Physiology and Chronic Health Evaluation; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; IAB, intensive care unit-acquired bacteremia; ICU, intensive care unit.

doi:10.1371/journal.pone.0083298.t003
stay, prolonged ventilator use, lower rate of successful weaning, and higher rate of ventilator dependence. Importantly, IAB was considered as the independent risk factor for ICU mortality and was associated with four-fold ICU mortality risk in comparison to no IAB. doi:10.1371/journal.pone.0083298.g003

Table 4. Univariate and Multivariate Cox Regression Analysis of Potential Risk Factors for ICU Mortality in the Study Patients (n = 1,453).

|                                | Univariate HR (95% CI) | Multivariate HR (95% CI) |
|--------------------------------|------------------------|--------------------------|
| Patient admitted from ordinary ward | 0.818 (0.620–1.080)    | -                        |
| Age                             | 1.002 (0.999–1.014)    | -                        |
| APACHE II on ICU admission      | 1.056 (1.029–1.084)**  | 1.056 (1.028–1.084)**    |
| IAB                             | 1.490 (1.101–2.020)**  | 1.510 (1.054–1.123)*     |

*p<0.05, **p<0.001. Multivariate Cox regression performed by the method of forward stepwise technique was applied. APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; HR, hazard ratio; IAB, intensive care unit-acquired bacteremia; ICU, intensive care unit.

doi:10.1371/journal.pone.0083298.t004
those patients without IAB. We further identified the independent risk factors for developing IAB in mechanically ventilated ICU patients as being on ventilator support due to COPD and CHF, and patients admitted from nursing home. We also described the clinical characteristics related to six specific bacterial species. To our knowledge, our study is the first to describe the clinical features and outcomes of IAB in mechanically ventilated ICU patients, and to report the clinical characteristics of IAB related to specific bacterial species. The results of our study can be utilized by intensivists to refine the management of IAB and may improve the quality of care in mechanically ventilated patients in the ICU setting.

The incidence of IAB in mechanically ventilated patients has not yet been determined. Here, we report that the cumulative incidence of IAB in ICU patients with MV was 4.2 episodes per 1,000 ICU days; that is lower than in previous studies showing a rate of 5.2 to 18.9 episodes per 1,000 ICU days in critically ill patients with and without MV [10,20,21]. The discrepancies may be due to the difference in the causative pathogens acquired in the ICUs between mechanically ventilated and non-mechanically ventilated critically ill patients. For example, infection by gram-negative microorganisms (83%) was dominant in our study, but the majority of IAB cases were attributed to gram-positive pathogens (73%) in the Laupland study [10]. Moreover, the median length of ICU stay in our study enrolling mechanically ventilated patients was also longer than that in a previous study (17.5 vs. 4.9 days) [10]. Older patient age in our study compared with that in other studies was also observed [10,20,21]. In our study, approximately one half of enrolled patients had a delay in recovering from medical critical conditions and were referred from other ICUs and ordinary wards. The patient sources in this study were different from those in other studies conducted in mixed ICUs with medical and surgical patients enrolled. The difference of patient sources may be associated with the discrepancy of age and IAB-related characteristics. These factors might be the reason for the low incidence of IAB in ICU patients under MV.

Nosocomial infections in ICU are associated with high mortality and medical expenditure [1–5]. In critically ill patients developing IAB, Laupland et al. reported a 2-fold increase in ICU mortality [10]. In our study, we demonstrated a 4-fold increase in ICU mortality in ICU patients under MV who developed IAB as compared to those who did not. We further analyzed the impact of IAB on the ICU mortality in the subgroup of patients with admitted APACHE II score >15, 15–24 and ≥25. The results showed that IAB led to a greater increase in APACHE II score in IAB patients with admitted APACHE II <15 compared to other subgroups and was significantly associated with the increase of ICU mortality across the wide range of disease severities. Importantly, in the

### Table 5. Baseline Characteristics of Study Patients with IAB Based on Bacterial Species.

|                  | K. pneumonia (n = 29) | P. aeruginosa (n = 21) | E. meningoseptica (n = 18) | A. baumannii (n = 11) | E. coli (n = 11) | MRSA (n = 16) | P     |
|------------------|-----------------------|------------------------|----------------------------|-----------------------|-----------------|--------------|-------|
| Age (y)          | 81 (76–86)            | 82 (78–89)             | 82 (78–88)                 | 81 (66–86)            | 82 (75–90)      | 82 (79–84)   | 0.821 |
| Apache II score  | 19.5±5.2              | 19.0±4.6               | 17.6±5.3                   | 21.8±6.0              | 17.6±3.3        | 20.9±4.8     | 0.181 |
| Comorbidity      |                       |                        |                            |                       |                 |              |       |
| Active malignancy| 4 (13.8)              | 2 (9.5)                | 2 (11.1)                   | 1 (9.1)               | 1 (9.1)         | 1 (6.3)      | 0.589 |
| COPD             | 14 (48.3)             | 13 (61.9)              | 11 (61.1)                  | 3 (27.3)              | 4 (36.4)        | 6 (37.5)     | 0.020 |
| CHF              | 8 (27.6)              | 7 (33.3)               | 8 (44.4)                   | 6 (54.5)              | 2 (18.2)        | 7 (43.8)     | 0.549 |
| Diabetes mellitus| 9 (31.0)              | 6 (28.6)               | 6 (33.3)                   | 5 (45.5)              | 3 (27.3)        | 5 (31.3)     | 0.637 |
| Primary bacteremia| 2 (6.9)              | 0 (0)                  | 12 (66.7)                  | 4 (36.4)              | 6 (54.5)        | 4 (25.0)     | 0.032 |
| Sources of pathogens |                   |                        |                            |                       |                 |              |       |
| Lungs            | 17 (58.6)             | 17 (81.0)              | 6 (20.7)                   | 5 (27.8)              | 6 (54.5)        | 1 (9.1)      | 0.000 |
| CVC              | 6 (20.7)              | 0 (0)                  | 1 (5.6)                    | 1 (5.6)               | 1 (9.1)         | 0 (0)        | 0.109 |
| Urinary tract    | 4 (13.8)              | 3 (14.3)               | 0 (0)                      | 0 (0)                 | 4 (36.4)        | 0 (0)        | 0.572 |
| Empyema          | 0 (0)                 | 1 (4.8)                | 0 (0)                      | 0 (0)                 | 0 (0)           | 1 (6.3)      | 1.000 |
| Multiple sets of positive hemoculture | 3 (10.3) | 3 (14.3) | 10 (55.6) | 2 (18.2) | 2 (18.2) | 7 (43.8) | 0.036 |
| Polymicrobial pathogens | 5 (17.2) | 5 (23.8) | 2 (11.1) | 1 (9.1) | 1 (9.1) | 1 (6.3) | 0.168 |
| Prior antibiotic use | 11 (37.9) | 15 (71.4) | 5 (27.8) | 5 (45.5) | 4 (36.4) | 7 (43.8) | 0.037 |
| Duration of ICU admission until IAB (d) | 22.0±15.8 | 20.1±16.0 | 21.3±16.8 | 14.8±10.4 | 10.2±6.5 | 17.0±14.9 | 0.187 |

Data are reported as mean ±SD or number (%). *Values were reported as median (interquartile range). Nonparametric Chi-Square test and Kruskal-Wallis test were used for the six most common pathogens of IAB to compare categorical and continuous variables, respectively, and p values are depicted in the Table. The Chi-Square test/Fisher exact test and Mann-Whitney U test were used for categorical and continuous variables, respectively, to identify the significant difference between patients harboring the individual pathogen versus patients not harboring this pathogen. APACHE, Acute Physiology and Chronic Health Evaluation; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVC, central venous catheter; IAB, ICU-acquired bacteremia; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus.

*p<0.05, IAB due to K. pneumonia vs. non-K.pneumonia;
*p<0.05, IAB due to P. aeruginosa vs. non-P. aeruginosa;
*p<0.05, IAB due to E. meningoseptica vs. non-E. meningoseptica;
*p<0.05, IAB due to E. coli vs. non-E. coli;
*p<0.05, IAB due to MRSA vs. non-MRSA.

doi:10.1371/journal.pone.0083298.t005
Table 6. Clinical Features at the Onset of IAB in Study Patients with IAB Based on Bacterial Species.

|                          | K. pneumonia (n = 29) | P. aeruginosa (n = 21) | E. meningoseptica (n = 18) | A. baumannii (n = 11) | E. coli (n = 11) | MRSA (n = 16) | P     |
|--------------------------|-----------------------|------------------------|-----------------------------|------------------------|-----------------|--------------|-------|
| APACHE II                | 24.4 ± 6.7            | 27.7 ± 6.9             | 22.8 ± 5.8                  | 26.7 ± 5.6             | 22.4 ± 7.2      | 26.3 ± 6.6   | 0.235 |
| Oxygen ratio (mmHg)      | 244.2 ± 163.7         | 220.6 ± 135.1          | 275.9 ± 182.5               | 245.4 ± 116.5          | 208.5 ± 101.3   | 243.8 ± 134.8| 0.922 |
| BUN (mg/dl)              | 78.0 ± 52.8           | 114.3 ± 63.7           | 60.9 ± 25.6                 | 105.0 ± 72.7           | 87.4 ± 62.5     | 89.3 ± 54.3  | 0.095 |
| Creatinine (mg/dl)       | 2.1 ± 1.5             | 2.4 ± 1.5              | 1.6 ± 1.0                   | 2.5 ± 1.5              | 2.2 ± 2.0       | 2.6 ± 1.4    | 0.466 |
| Effective empiric antibiotic | 15 (51.7)           | 14 (86.7)              | 3 (16.7)                    | 7 (63.6)               | 6 (54.5)        | 8 (50.0)     | 0.028 |
| Time delay until appropriate antibiotic used (h) | 37.8 ± 42.4          | 240 ± 30.9             | 77.5 ± 47                   | 46.2 ± 49.4            | 34.4 ± 32.8     | 38.1 ± 36.9  | 0.024 |
| Shock                    | 10 (34.5)             | 9 (42.9)               | 2 (11.1)                    | 5 (45.5)               | 2 (18.2)        | 4 (25.0)     | 0.049 |
| Need for acute hemodialysis | 5 (17.2)            | 5 (23.8)               | 0 (0)                       | 1 (9.1)                | 0 (0)           | 4 (25.0)     | 0.413 |
| Organ dysfunction (No.)  | 0.8 ± 1.0             | 1.6 ± 1.4              | 0.5 ± 0.5                   | 0.9 ± 1.1              | 0.9 ± 0.9       | 1.2 ± 1.2    | 0.152 |
| ICU stay (d)             | 546 ± 37.0            | 38.4 ± 24.0            | 49.4 ± 25.9                 | 41.9 ± 15.7            | 41.7 ± 26.3     | 34.1 ± 19.6  | 0.253 |
| Successful weaning       | 10 (34.5)             | 6 (28.6)               | 9 (50.0)                    | 6 (54.5)               | 5 (45.5)        | 9 (56.3)     | 0.721 |
| 28-day ventilator-free days (d) | 3.0 ± 7.1         | 3.1 ± 7.2              | 2.8 ± 6.7                   | 6.7 ± 8.3 c            | 6.8 ± 9.6       | 6.0 ± 8.0    | 0.102 |
| ICU mortality            | 15 (51.7)             | 12 (57.1)              | 10 (55.6)                   | 1 (9.1) y              | 3 (27.3)        | 7 (43.8)     | 0.003 |

Data are reported as mean ± S.D. or number (%). Nonparametric Chi-Square test and Kruskal-Wallis test were used for the six most common pathogens of IAB to compare categorical and continuous variables, respectively, and p values are depicted in the table. The Chi-Square test/Fisher exact test and Mann-Whitney U test were used for categorical and continuous variables, respectively, to identify the significant difference between patients harboring the individual pathogen versus patients not harboring this pathogen. APACHE, Acute Physiology and Chronic Health Evaluation; BUN, blood urea nitrogen; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus.

*p<0.05, IAB due to P. aeruginosa vs. non-P. aeruginosa;
*p<0.05, IAB due to E. meningoseptica vs. non-E. meningoseptica;
*p<0.05, IAB due to A. baumannii vs. non-A. baumannii.

doi:10.1371/journal.pone.0083298.t006
subgroups with less severe severity of disease (APACHE II < 15 and 15–24), excess ICU mortality of approximately 40% was observed in patients with IAB as compared to those without IAB. Our study showed that IAB not only had an impact on patient survival but also hampered the discontinuation of ventilator in mechanically ventilated patients in the ICU setting.

It is important to identify risk factors for intensivists to manage nosocomial infections early in the ICU setting. Several risk factors for the development of IAB, including younger age, immune-compromised status, diabetes mellitus, admission to ICU, higher therapeutic intervention scoring system scores, higher admitting APACHE II, and increased length of ICU stay, have been mentioned in critically ill patients [10, 20, 29]. In ICU patients with MV, we identified older age as the risk factor for IAB that was different from the population-based assessment of IAB from Laupland's study [10]. Severe disease measured by the admitting APACHE II score was considered as a risk factor for IAB in our study and others [10, 20]. We also reported that in ICU patients under MV, patient admitted from nursing homes, not home, was associated with a higher risk of developing IAB. Notably, in the multivariate Cox regression analysis, we identified ventilator support for COPD and CHF, and patients admitted from nursing home as the independent risk factors for developing IAB. Although patients with respiratory failure due to pneumonia and sepsis were potentially associated with developing bacteremia simultaneously, both of those acute illnesses seemingly had less influence on the bacteremia development after ICU admission. The above-mentioned information enables intensivists to become more aware of the mechanically ventilated patients who are at the risk of developing IAB and initiate the treatment of IAB early in the ICU setting.

One of the important findings in our study was the clinical characteristics related to specific bacterial species. We identified that IAB due to P. aeruginosa was significantly associated with prior use of antibiotics, and the lung was the most likely entry site with polymicrobial infection. These patients were frequently implicated with distal organ dysfunction, and in particular, renal failure. Other investigators also report that IAB due to P. aeruginosa is more likely to be nonrespondent on the basis of continued need for vasopressor support [23, 24]. It is noted that E. meningoseptica was one of the most commonly identified pathogens in our study. We observed that patients with IAB due to E. meningoseptica presented with milder illness in general but longer duration of delayed appropriate antibiotic treatment as compared to those with IAB due to P. aeruginosa. The inadequate and/or delayed appropriate antibiotic treatment may potentially have increased the risk of death in patients with E. meningoseptica bacteremia and led to a similar rate of ICU mortality between IAB due to E. meningoseptica and P. aeruginosa. [23–27]. Another interesting finding of our study is that patients with IAB due to A. baumannii had better outcomes, with a lower ICU mortality rate and shorter ventilator days. This observation may be explained by the fact that most A. baumannii causing IAB (72.7%) were not multiple-drug resistant [20]; therefore, these patients generally responded well to antibiotic therapy. Urinary tract infection is one of the important nosocomial infections, and E. coli is reported to be the most common pathogen that potentially causes the development of IAB in the ICU [29]. In our study, IAB due to E. coli mostly originated from the urinary tract and significantly developed earlier (mean time of 10 days after ICU admission). In our study, MRSA was the most common gram-positive bacteria for IAB in mechanically ventilated ICU patients and was mostly related to central catheter infection. Kullar et al. also report that catheter-related infections and endocarditis are the most common sites of MRSA bacteremia for older (65 years and older) and younger (less than 65 years) adults, respectively [30]. We also identified that IAB due to MRSA was associated with multiple sets of positive hemoculture and made necessary immediate removal of the CVC.

There are several limitations in our study. The study was conducted in a respiratory ICU, where gram-negative microorganisms were the main pathogens of IAB. The patients enrolled were elderly and ventilated for a long period. This overall picture of IAB may be different in a general multidisciplinary ICU containing a mix of medical and surgical patients. Second, the patients were followed until ICU discharge; thus, the impact of IAB on long-term outcomes was not evaluated. Third, the study was retrospective and observational, and we did not prospectively evaluate, assess and examine the prevalence of bacteremia under a standardized protocol for all critically ill patients, independent of the underlying diagnoses and the application of mechanical ventilation.

Conclusions

We reported that IAB was the independent risk factor for ICU mortality in mechanically ventilated ICU patients and was significantly associated with longer length of ICU stay, prolonged ventilator days, lower rate of successful ventilator weaning, and higher rate of ventilator dependency. The risk factors for developing IAB and the clinical characteristics related to specific bacterial species identified in our study may help intensivists develop the appropriate strategies to refine the management of IAB in mechanically ventilated patients in the ICU setting.

Acknowledgments

The authors thank all the health care workers of the RTCU at the Taipei Veterans General Hospital for their valuable contribution to the patient care. Dr. Benjamin Ing-Tiau Kuo for the statistical review, Dr. Kwok-Woon Yu for the microbiological review and Mr. Matt Nicodemus for his help in language editing.

Author Contributions

Conceived and designed the experiments: HKK TCL WKY JHW ASS HZ YRK. Wrote the paper: HKK TCL WKY JHW. Contributed reagents/materials/analysis tools: HKK TCL WKY JHW ASS HZ YRK. Analyzed the data: HKK ASS HZ YRK. Helped in language editing: HKK TCL WKY JHW ASS HZ YRK.

References

1. Damas P, Ledoux D, Nys M, Monchi M, Wiesen P, et al. (2008) Intensive care unit-acquired infection and organ failure. Intensive Care Med 34:856–864.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303–1310.
3. Suljagić V, Cobešić M, Jancovíc Š, Mirović V, Marković-Denić L, et al. (2005) Nosocomial bloodstream infections in ICU and non-ICU patients. Am J Infect Control 33:333–340.
4. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, et al. (2009) International consensus on the prevalence and outcomes of infection in intensive care units. JAMA 302:2323–2329.
5. Digiovine B, Chenoweth C, Watts C, Higgins M (1999) The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 160:976–983.
6. Garrant-Orgeas M, Timsit JF, Taillé M, Misrot B, Zahar JR, et al. (2006) Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis 42:1118–1126.
7. Renaud B, Brun-Buisson C, ICU-Bacteremia Study Group (2001) Outcomes of primary and catheter-related bacteremia: a cohort and case-control study in critically ill patients. Am J Respir Crit Care Med 163:1584–1590.
8. Pittet D, Tarara D, Wenzel RP (1994) Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 271:1398–1401.

9. Esteban A, Alzueta A, Frutos F, Alia I, Brochard L, et al. (2002) Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 287:345–353.

10. Laupland KB, Zygun DA, Davies HD, Church DL, Louie TJ, et al. (2002) Population-based assessment of intensive care unit-acquired bloodstream infections in adults: incidence, risk factors and associated mortality rate. Crit Care Med 30:2462–2467.

11. Blot S, Vanderwoude K, Hoete E, De Waele J, Kini K, et al. (2003) Absence of excess mortality in critically ill patients with nosocomial Escherichia coli bacteremia. Infect Control Hosp Epidemiol 24:912–913.

12. Blot S, Vanderwoude K, Colardyn F (2003) Evaluation of outcome in critically ill patients with nosocomial Enterobacter bacteremia: result of a matched cohort study. Chest 123:1206–1213.

13. Blot S, Vanderwoude K, Colardyn F (2002) Clinical impact of nosocomial Klebsiella bacteremia in critically ill patients. Eur J Clin Microbiol Infect Dis 21:471–473.

14. Blot S, Vanderwoude K, Colardyn F (2003) Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Medicine 29:471–475.

15. Blot S, Vanderwoude K, Hoete E, Colardyn F (2003) Reappraisal of attributable mortality in critically ill patients with nosocomial bacteremia involving Pseudomonas aeruginosa. J Hosp Infect 53:18–24.

16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829.

17. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D (2000) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 28:S20–S54.

18. Richards MJ, Edwards JR, Culver DH, Gaynes RP (1999) Nosocomial infections in medical intensive care units in the United States. Crit Care Med 27:887–892.

19. Laupland KB, Kirkpatrick AW, Church DL, Ross T, Grespon DB (2004) Intensive-care-unit-acquired bloodstream infections in a regional critically ill population. J Hosp Infect 58:137–145.

20. Thompson DS (2008) Estimates of the rate of acquisition of bacteremia and associated excess mortality in a general intensive care unit a 10 year study. J Hosp Infect 69:56–61.

21. Michalopoulos A, Falagas ME, Karatzas DC, Alexandropoulou P, Papadaki E, et al. (2011) Epidemiology, clinical characteristics, and risk factors for adverse outcome in multiresistant gram-negative primary bacteremia of critically ill patients. Am J Infect Control 39:396–400.

22. Osman S, Ward S, Fraser VJ, Kollef MH (2004) Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 125:607–616.

23. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, et al. (2003) Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 37:741–751.

24. Hsu MS, Liao CH, Huang YT, Liu CY, Yang CJ, et al. (2011) Clinical features, antimicrobial susceptibilities, and outcomes of Elkhartilinga meningoseptica (Chryseobacterium meningosepticum) bacteremia at a medical center in Taiwan, 1998–2006. Eur J Clin Microbiol Infect Dis 30:1271–1278.

25. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH, et al. (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146–155.

26. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, et al. (2005) Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 49:769–766.

27. Lu PL, Liu YC, Toh HS, Lee YL, Liu YM, et al. (2012) Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009–2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 40:83–89.

28. Kullar R, Rybak MJ, Kaye KS (2013) Comparative epidemiology of bacteremia due to methicillin-resistant Staphylococcus aureus between older and younger adults: a propensity score analysis. Infect Control Hosp Epidemiol 34:400–406.